EcoDrugPlus

Histone Deacetylase 4

Ensembl ID : ENSOJAG00000000222
Gene Symbol: HDAC4
1 Cross references
196 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSOJAG00000014523
Gene Symbol: HDAC5
1 Cross references
194 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSOJAG00000018904
Gene Symbol: HDAC7
1 Cross references
189 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSOJAG00000016782
Gene Symbol: HDAC8
1 Cross references
205 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOJAG00000010749
Gene Symbol: HCN4
1 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSOJAG00000020205
Gene Symbol: HCN4
1 Cross references
220 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSOJAG00000006524
Gene Symbol: HCRTR2
1 Cross references
203 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSOJAG00000001342
Gene Symbol: IKBKB
1 Cross references
199 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSOJAG00000000617
Gene Symbol: INPP5D
1 Cross references
215 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSOJAG00000022139
Gene Symbol: INSRA
1 Cross references
213 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSOJAG00000018677
Gene Symbol: INSRB
1 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSOJAG00000018672
Gene Symbol: IGF1RA
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).